Literature DB >> 34383001

Errors in Abstract and Results.

.   

Abstract

Entities:  

Year:  2021        PMID: 34383001      PMCID: PMC8446817          DOI: 10.1001/jamaoncol.2021.4021

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  1 in total

1.  Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.

Authors:  Thomas Hatschek; Theodoros Foukakis; Judith Bjöhle; Tobias Lekberg; Hanna Fredholm; Ellinor Elinder; Ana Bosch; Gyula Pekar; Henrik Lindman; Aglaia Schiza; Zakaria Einbeigi; Jamila Adra; Anne Andersson; Lena Carlsson; Ann Charlotte Dreifaldt; Erika Isaksson-Friman; Susanne Agartz; Edward Azavedo; Per Grybäck; Mats Hellström; Hemming Johansson; Claudia Maes; Ioannis Zerdes; Johan Hartman; Yvonne Brandberg; Jonas Bergh
Journal:  JAMA Oncol       Date:  2021-09-01       Impact factor: 33.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.